Novo Nordisk’s high-dose Wegovy increases weight loss and remains safe
The therapy was reported to be well-tolerated, with a good safety profile.
Therapy Area
Palisade Bio begins MAD cohorts of Phase Ia/b ulcerative colitis therapy trial
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial
Sanofi to increase competition in atopic dermatitis market after Dupixent success
Evaxion concludes subject dosing in Phase II trial of melanoma vaccine
WHO reports eight deaths from suspected Marburg outbreak in Tanzania
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Pfizer’s Phase III bladder cancer therapy trial meets primary endpoint
